Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...
International students’ housing challenges call for policy action
By addressing students’ challenges and the barriers they encounter, and by supporting their successes, we can ensure Canada ...